Formulation Development
Zerion Pharma & Hovione Extend Partnership to Cover Use of Dispersome Technology Platform in Nutraceuticals
Hovione and Zerion Pharma A/S (Zerion) recently announced an extension of their collaboration on Zerion’s Dispersome technology into the nutraceutical/dietary….
Oculis Announces Phase 2 Data Showing Topical Eye Drops Anti-TNFα Agent Licaminlimab Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease
Oculis S.A. recently announced results of the double blinded, multicenter and placebo controlled Phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe….
Immatics Announces First Cancer Patient Treated With Second-Generation ACTengine TCR-T Candidate
Immatics N.V. recently announced the treatment of the first patient in its Phase 1b expansion cohort C (NCT03686124) evaluating IMA203CD8, the company’s second-generation TCR-T monotherapy…
Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the US
Belite Bio, Inc. recently announced it has commenced enrollment for the US Phase 3 clinical trial of LBS-008 in patients with Stargardt Disease (STGD1), a…
Lonza Strengthens Micronization Portfolio With the Introduction of X-Ray Powder Diffraction Capability
Lonza has expanded the range of particle engineering services offered by its Monteggio (CH) site through the introduction of X-ray powder diffraction (XRPD). This rapid analytical technique provides additional….
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - Expressing Cancers
Cue Biopharma, Inc. recently announced it has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102, its second clinical drug candidate…
Agios Announces Publication of Phase 3 ACTIVATE-T Data Demonstrating Benefits of PYRUKYND for Adults With Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc. recently announced data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular….
Kapruvia Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022
Cara Therapeutics, Inc. and Vifor Fresenius Medical Care Renal Pharma recently announced they have received approval for Kapruvia from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia will be the first….
AUM Biosciences Receives FDA Orphan Drug Designation for the Treatment of Solid Tumors With the NTRK Fusion Gene
AUM Biosciences recently announced the US FDA has granted Orphan Drug Designation (ODD) to AUM601, a highly selective, oral small molecule that inhibits not only…
Blue Water Vaccines Announces Exploration of its VLP Platform for Use in Monkeypox Vaccine Candidate
Blue Water Vaccines Inc. recently announced the company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion…
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Selective Allosteric TYK2 Inhibitor VTX958
Ventyx Biosciences, Inc. recently announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a…
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the US for Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function & Regeneration of Bowel Epithelium
Immunic, Inc. recently announced it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application 16/646130 titled Compound…
Artelo Biosciences Reports Positive Preclinical Results for Novel Inhibitor to Fatty Acid Binding Protein 5
Artelo Biosciences, Inc. recently announced publication of preclinical results indicating a novel fatty acid binding protein 5 (FABP5) inhibitor from the company’s FABP inhibitor platform…
Addex & Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
Addex Therapeutics recently announced its collaboration agreement with Indivior PLC for discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)…
Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE 81 mg
PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on its clinically validated and patent-protected PLxGuard that has the potential to improve…
Kymanox Announces First Executive Advisor: Fran DeGrazio
Kymanox Corporation is honored to announce Fran DeGrazio to the newly formed Kymanox Executive Advisors team. This team of highly distinguished industry executives has led…
Priority Review Granted for the First Oral & First New SERD in 20 years to Treat Metastatic Breast Cancer
The Menarini Group and Stemline Therapeutics recently announced the US FDA has accepted the company’s New Drug Application (NDA) for elacestrant, an investigational selective estrogen…
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership With Ginkgo Bioworks
Synlogic, Inc. recently announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks The new candidate, SYNB2081, is a Synthetic…
Catalent to Acquire Metrics Contract Services for $475 Million
Catalent, Inc. recently announced it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in….
VYNE Therapeutics Announces Results From Phase 2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
VYNE Therapeutics Inc. recently announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic…
